UPLOAD Filing
Scienture Holdings, Inc.
Date: Aug. 19, 2025 · CIK: 0001382574 · Accession: 0000000000-25-008783
AI Filing Summary & Sentiment
Reasoning
Letter
Re: Scienture Holdings, Inc. Draft Registration Statement on Form S-3 Submitted August 15, 2025 CIK No. 0001382574 Dear Narasimhan Mani:
August 19, 2025
Narasimhan Mani Chief Executive Officer Scienture Holdings, Inc. 20 Austin Blvd. Commack, NY 11725
This is to advise you that we do not intend to review your registration statement.
We request that you publicly file your registration statement and non-public draft submission on EDGAR at least two business days prior to the requested effective date and time. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Doris Stacey Gama at 202-551-3188 with any questions.
Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Louis D. Kern, Esq.
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> August 19, 2025 Narasimhan Mani Chief Executive Officer Scienture Holdings, Inc. 20 Austin Blvd. Commack, NY 11725 Re: Scienture Holdings, Inc. Draft Registration Statement on Form S-3 Submitted August 15, 2025 CIK No. 0001382574 Dear Narasimhan Mani: This is to advise you that we do not intend to review your registration statement. We request that you publicly file your registration statement and non-public draft submission on EDGAR at least two business days prior to the requested effective date and time. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Doris Stacey Gama at 202-551-3188 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Louis D. Kern, Esq. </TEXT> </DOCUMENT>